Micro RNA Expression and Prognosis in Low-grade Non-invasive Urothelial Carcinoma

dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorDIP, Nelson
dc.contributor.authorREIS, Sabrina T.
dc.contributor.authorABE, Daniel K.
dc.contributor.authorVIANA, Nayara I.
dc.contributor.authorMORAIS, Denis R.
dc.contributor.authorMOURA, Caio M.
dc.contributor.authorKATZ, Betina
dc.contributor.authorSILVA, Iran A.
dc.contributor.authorSROUGI, Miguel
dc.contributor.authorLEITE, Katia R. M.
dc.date.accessioned2015-07-01T20:15:59Z
dc.date.available2015-07-01T20:15:59Z
dc.date.issued2014
dc.description.abstractPurpose: To analyze a possible correlation between a miRNA expression profile and important prognostic factors for pTa urothelial carcinomas (UC), including tumor size, multiplicity and episodes of recurrence. Materials and Methods: Thirty low-grade non-invasive pTa bladder UC from patients submitted to transurethral resection were studied, in a mean follow-up of 17.7 months. As controls, we used normal bladder tissue from five patients submitted to retropubic prostatectomy to treat benign prostatic hyperplasia. Extraction, cDNA and amplification were performed for 14 miRNAs (miR-100, -10a, -21, -205, -let7c, -143, -145, -221, -223, -15a, -16, -199a and -452) using specific kits, and RNU-43 and -48 were used as endogenous controls. Statistical tests were used to compare tumor size, multiplicity and episodes of recurrence with miRNAs expression profiles. Results: There was a marginal correlation between multiplicity and miR-let7c over- expression. For all others miRNA no correlation between their expression and prognostic factors was found. Conclusion: We did not find differences for miRNAs expression profiles associated with prognostic factors in tumor group studied. The majority of miRNAs are down-regulated, except miR-10a, over-expressed in most of cases, seeming to have increased levels in tumor with more unfavorable prognostic factors. More studies are needed in order to find a miRNA profile able to provide prognosis in pTa UC to be used in clinical practice.
dc.description.indexMEDLINE
dc.identifier.citationInternational Braz J Urol, v.40, n.5, p.644-649, 2014
dc.identifier.doi10.1590/S1677-5538.IBJU.2014.05.09
dc.identifier.eissn1677-6119
dc.identifier.issn1677-5538
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/9236
dc.language.isoeng
dc.publisherBRAZILIAN SOC UROL
dc.relation.ispartofInternational Braz J Urol
dc.rightsopenAccess
dc.rights.holderCopyright BRAZILIAN SOC UROL
dc.subjectMicroRNAs
dc.subjectUrinary Bladder Neoplasms
dc.subjectPrognosis
dc.subjectMolecular Biology
dc.subject.othersuperficial bladder-cancer
dc.subject.othergrowth-factor receptor-3
dc.subject.othercell-carcinoma
dc.subject.othergene-mutations
dc.subject.otherfgfr3
dc.subject.otherras
dc.subject.otherpathways
dc.subject.othersurvival
dc.subject.otherfamily
dc.subject.otherstage
dc.subject.wosUrology & Nephrology
dc.titleMicro RNA Expression and Prognosis in Low-grade Non-invasive Urothelial Carcinoma
dc.title.alternativeMicro RNA expression and prognosis in low-grade non-invasive urothelial carcinoma
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus8
hcfmusp.contributor.author-fmusphcNELSON GASPAR DIP JUNIOR
hcfmusp.contributor.author-fmusphcSABRINA THALITA DOS REIS FARIA
hcfmusp.contributor.author-fmusphcDANIEL KANDA ABE
hcfmusp.contributor.author-fmusphcNAYARA IZABEL VIANA MOURA
hcfmusp.contributor.author-fmusphcDENIS REIS MORAIS
hcfmusp.contributor.author-fmusphcCAIO MARTINS MOURA
hcfmusp.contributor.author-fmusphcBETINA STIFELMAN KATZ
hcfmusp.contributor.author-fmusphcIRAN AMORIM DA SILVA
hcfmusp.contributor.author-fmusphcMIGUEL SROUGI
hcfmusp.contributor.author-fmusphcKATIA RAMOS MOREIRA LEITE
hcfmusp.description.beginpage644
hcfmusp.description.endpage649
hcfmusp.description.issue5
hcfmusp.description.volume40
hcfmusp.origemWOS
hcfmusp.origem.pubmed25498275
hcfmusp.origem.scieloSCIELO:S1677-55382014000500644
hcfmusp.origem.scopus2-s2.0-84920065306
hcfmusp.origem.wosWOS:000348606000009
hcfmusp.publisher.cityRIO DE JANEIRO
hcfmusp.publisher.countryBRAZIL
hcfmusp.relation.referenceAli-El-Dein B, 2003, BJU INT, V92, P393, DOI 10.1046/j.1464-410X.2003.04360.x
hcfmusp.relation.referenceBakkar AA, 2003, CANCER RES, V63, P8108
hcfmusp.relation.referenceBorden LS, 2005, CURR OPIN ONCOL, V17, P275, DOI 10.1097/01.cco.0000156985.47984.9e
hcfmusp.relation.referenceBotteman MF, 2003, PHARMACOECONOMICS, V21, P1315
hcfmusp.relation.referenceCastillo-Martin M, 2010, UROL ONCOL-SEMIN ORI, V28, P401, DOI 10.1016/j.urolonc.2009.04.019
hcfmusp.relation.referenceCatto JWF, 2009, CANCER RES, V69, P8472, DOI 10.1158/0008-5472.CAN-09-0744
hcfmusp.relation.referenceCimmino A, 2006, P NATL ACAD SCI USA, V103, P2464, DOI 10.1073/pnas.0510793103
hcfmusp.relation.referenceDip N, 2012, J UROLOGY, V188, P1951, DOI 10.1016/j.juro.2012.07.004
hcfmusp.relation.referenceDip N, 2011, J MOL BIOMARK DIAGN, V2, P1
hcfmusp.relation.referenceEnokida H, 2008, INT J CLIN ONCOL, V13, P298, DOI 10.1007/s10147-008-0811-1
hcfmusp.relation.referenceJebar AH, 2005, ONCOGENE, V24, P5218, DOI 10.1038/sj.onc.1208705
hcfmusp.relation.referenceJohnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
hcfmusp.relation.referenceLamm DL, 2000, J UROLOGY, V163, P1124, DOI 10.1016/S0022-5347(05)67707-5
hcfmusp.relation.referenceLeite KRM, 2011, UROL ONCOL-SEMIN ORI, V29, P265, DOI 10.1016/j.urolonc.2009.02.002
hcfmusp.relation.referenceLewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
hcfmusp.relation.referenceLin TX, 2009, J UROLOGY, V181, P1372, DOI 10.1016/j.juro.2008.10.149
hcfmusp.relation.referenceMarsit CJ, 2007, CARCINOGENESIS, V28, P1745, DOI 10.1093/carcin/bgm116
hcfmusp.relation.referenceMartinez-Torrecuadrada JM, 2005, CLIN CANCER RES, V11, P6280, DOI 10.1158/1078-0432.CCR-05-0282
hcfmusp.relation.referenceMcConkey DJ, 2010, UROL ONCOL-SEMIN ORI, V28, P429, DOI 10.1016/j.urolonc.2010.04.008
hcfmusp.relation.referenceNARAYANA AS, 1983, J UROLOGY, V130, P56
hcfmusp.relation.referenceOrnitz DM, 1996, J BIOL CHEM, V271, P15292
hcfmusp.relation.referenceOrom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001
hcfmusp.relation.referencePandith AA, 2013, UROL ONCOL-SEMIN ORI, V31, P398, DOI 10.1016/j.urolonc.2010.07.014
hcfmusp.relation.referenceSiegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
hcfmusp.relation.referenceSOLOWAY MS, 1980, CANCER, V45, P1856
hcfmusp.relation.referencevan Rhijn BWG, 2001, CANCER RES, V61, P1265
hcfmusp.relation.referenceVeerla S, 2009, INT J CANCER, V124, P2236, DOI 10.1002/ijc.24183
hcfmusp.relation.referenceZhang ZT, 2001, ONCOGENE, V20, P1973, DOI 10.1038/sj.onc.1204315
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication7b98028d-1464-41f7-b473-7326a36a8d3c
relation.isAuthorOfPublication73be4bca-f8ad-443f-90b5-10e2e62b1e27
relation.isAuthorOfPublicationa880b3b6-276f-41d5-bac4-910de6024fcc
relation.isAuthorOfPublication32f63bee-3f86-4e8d-b307-f29f080dd7b4
relation.isAuthorOfPublication7af4bd17-a1d2-4c42-a4af-e0919576a464
relation.isAuthorOfPublicationbc28b381-6994-4655-9f48-9bc7136e4db9
relation.isAuthorOfPublication01d7a5da-3983-420d-b86f-291cd9d6378b
relation.isAuthorOfPublicationb276e0c0-431e-426d-879c-06108f4cc785
relation.isAuthorOfPublicationcff561dd-5732-4af5-abe9-538da0cdf4d2
relation.isAuthorOfPublication23772d3b-0da7-472f-8d56-e6312dbf95c1
relation.isAuthorOfPublication.latestForDiscovery7b98028d-1464-41f7-b473-7326a36a8d3c
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
art_DIP_Micro_RNA_Expression_and_Prognosis_in_Lowgrade_Noninvasive_2014.PDF
Tamanho:
128.91 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)